Introduction
High fidelity DNA replication and faithful chromosome segregation are fundamentally essential processes allowing cells to transmit their genetic information to the descendants. Failures in maintaining genetic stability may cause their death or such abnormal phenotypes as malignancy. Cancer cells frequently exhibit marked chromosome abnormalities, which are generally considered to reflect defects in the mechanisms that ensure genetic stability. Chromosome abnormalities can be classified broadly into numerical (i.e., aneuploidy) and structural alterations (e.g., deletion, translocation, homogenously staining region (HSR), double minutes (DMs)) of chromosomes. Such chromosomal alterations, which are indeed present in most human tumors, are especially marked in solid tumors, including lung cancer, but the underlying mechanisms and the biological and clinical significance have not been elucidated to any satisfactory degree. However, recent progress in molecular and cellular biology as well as technical development in cytogenetics has shed light on these important issues related to cancer development and progression, providing evidence for the involvement of failures in the cell cycle checkpoint control and defects in the DNA double-strand break (DSB) repair system in the genesis of chromosome instability (CIN) .
In the present article, we will give a brief overview of chromosomal alterations thus far reported in lung cancer, and then summarize recent progress in the understanding of possible underlying mechanisms of CIN and its potential involvement in the development of lung cancer, with reference to recent findings in the analysis of other human cancers as well as in those of various organisms such as mice and yeast.
Numerical and structural chromosome abnormalities in human lung cancer
Early in the 20th century, Theodor Boveri described abnormal mitosis and chromosomal changes in cancers, and hypothesized that malignancy of the mammalian somatic cells resulted from an abnormal chromosomal constitution (Boveri, 1914) . Later on, Philadelphia chromosome (Ph 1 ) was identified in the majority of chronic myelocytic leukemia (CML), supporting Boveri's hypothesis. To date, a large number of additional non-random chromosomal translocations have been identified especially in tumors of hematopoietic lineage (Heim and Mitelman, 1989) .
In contrast, in most malignancies of epithelial origin, including lung cancer, studies on the possible involvement of chromosomal alterations in carcinogenesis were hampered by technical limitations. Conventional karyotyping analysis principally requires the presence of mitotic cells in their preparations, but primary solid tumors often provide too few mitotic cells. Furthermore, the presence of very complex karyotypes in solid tumor cells from numerical and structural points of view often made it difficult to accomplish the karyotyping analysis satisfactorily. In human lung cancer, nearly all cases show complex karyotypes with multiple structural and numerical abnormalities (Testa and Siegfried, 1992; Testa, 1996) . Approximately 70 -80% of lung cancer cases carry from a near triploid to tetraploid ranges of karyotypes with various structural abnormalities including deletion, non-reciprocal translocation and isochromosome. DMs are also observed in 20 -30% of small cell lung cancer (SCLC) and 10 -20% of non-small cell lung cancer (NSCLC).
Fluorescence activated cell sorter (FACS) and image cytometric analyses can assess any overall increase or decrease in the DNA content of a tumor cell, not only in the mitotic phase, but also in the interphase, even with fixed and paraffin-embedded specimens. Numerous studies have been reported on the relationships between abnormal DNA content reflecting aneuploidy and various clinical features including histological type, clinical stage, sensitivity to chemotherapy, and prognosis. Although most of such studies have demonstrated the presence of markedly abnormal DNA contents in 65 -85% of NSCLC and SCLC, the relationship between aneuploidy and patient survival remains controversial. In this connection, Choma et al. (2001) recently conducted a meta-analysis of data obtained with 4033 NSCLC patients in 35 previously published studies, demonstrating that patients with tumors with abnormal DNA content had a significantly shorter survival duration than those with normal DNA content reflecting diploid or psuedodiploid chromosomes. In contrast, the prognostic value of the degree of abnormal DNA ploidy does not seem to be evident in SCLC (Oud et al., 1989; Jackson-York et al., 1991; Viren et al., 1997) .
Fluorescence in situ hybridization (FISH) analysis with centromeric probes of a specific chromosome(s) can obtain information of losses and gains of the specific chromosome in each cell of a whole tissue section or cultured cells. Although it has been suggested that cancer cells possess persistent CIN based on observations of the karyotypic heterogeneity even within the same tumor, it has remained rather ambiguous as to whether chromosomes in cancer cells are indeed unstable, which would reflect the presence of persistent CIN. Lengauer et al. (1997) demonstrated by means of FISH analysis that aneuploidy in colorectal cancer cell lines is not a result of a few past catastrophic processes of missegregations, but rather that it reflects the persistence of an unstable karyotypic state. Haruki et al. (2001) have also demonstrated persistent CIN in human lung cancer cell lines with a notable association with aneuploid karyotypes.
Recently invented novel means of cytogenetic analysis, such as comparable genomic hybridization (CGH) and spectral karyotyping (SKY), have allowed a fine mapping of chromosomal losses or gains in cancer cells, and have revealed clear pictures of nonrandom losses and gains of particular chromosomal portions even in solid tumors. CGH enables precise analysis of losses and gains of chromosomal segments by competitive hydridization between cancer and normal DNAs on a karyotype spread of normal cells, and thus does not require the abundant presence of mitotic cells in primary cancer cells (Kallioniemi et al., 1992) . CGH studies have revealed novel and histological type-specific gains and losses of chromosome segments in human lung cancers (Schwendel et al., 1997; Levin et al., 1994 Levin et al., , 1995 Petersen et al., 1997a,b) , in addition to those previously reported by conventional cytogenetic approaches.
SKY is also a powerful technique, which is based on 24-color, whole chromosome-painting assay (Liyanage et al., 1996; Veldman et al., 1997) . SKY makes it possible to detect subtle karyotypic alterations, which would be otherwise overlooked, as well as to identify the chromosomal origins of abnormalities, which would have been designated merely as a 'marker chromosome' in conventional karyotyping analysis. To date, only a few SKY studies have been reported in lung cancers, but these have resulted in the identification of a greater degree of chromosomal rearrangements than those detected by previous Gbanding and CGH analyses (Luk et al., 2001; Dennis and Stock, 1999) .
As a consequence, it has become evident that the losses and gains of chromosomes in lung cancer are not random. It is also notable that although lung cancers do share similar chromosomal abnormalities in common, they also have certain histologic type-specific characteristics of chromosomal abnormalities. The short arm of chromosome 3 (3p) was among the first to be identified as a non-randomly affected chromosomal region in lung cancer (Whang-Peng et al., 1982) . In addition to 3p, it has been reported that chromosomal gains are frequent in 5p, the long arm of chromosome 8 (8q), 17q and 19q in NSCLC and 3q, 5p, 8p and Xq in SCLC, whereas chromosome losses are frequent in 1p, 4q, 5q, 6q, 8p, 9p, 13q and 17p in NSCLC and 5q, 13q and 17p in SCLC (Schwendel et al., 1997; Levin et al., 1994 Levin et al., , 1995 Petersen et al., 1997a,b; Michelland et al., 1999) .
There is considerable circumstantial evidence for the involvement of CIN in the initiation, progression, and metastasis of human malignancies. Notable examples are the existence of hereditary CIN syndromes including the Ataxia telangiectasia (A-T), Nijmegen breakage, Bloom's and Werner syndromes as well as Fanconi anemia, all of which are known to be predisposed to various cancers (Wright, 1999; Vessey et al., 1999) . A few mitotic checkpoint genes important for proper chromosome segregation have been found to be mutated in human cancer cells (Cahill et al., 1998; Nomoto et al., 1999; Percy et al., 2000; Hernando et al., 2001; Gemma et al., 2000; Sato et al., 2000) , while mice deficient in the Mad2 mitotic checkpoint gene have been shown to specifically develop lung tumors with the CIN phenotype (Michel et al., 2001) . Furthermore, the precise assay of chromosome aneuploidy in primary tumors with G-banding, SKY and CGH have revealed the presence of specific chromosomal abnormalities, which correlate with distinct tumor type, suggesting their non-random nature (Seizinger et al., 1991; Rooney et al., 1999) .
What would then be the consequence of CIN in terms of its contributions to tumorigenesis and progression? Several possible explanations may be applicable, although it should be noted that these explanations are not exclusive of one another: (1) CIN alters chromosomal configurations, and increases the gene dosage of growth-promoting genes, such as oncogenes, and decreases the gene dosage of negative regulators, such as tumor suppressor genes on the affected chromosomes. Cancer cell clones with such advantageous changes would eventually develop predominance during the tumor progression processes. Gene amplification of members of the myc gene family may be one of the typical examples. (2) CIN accelerates the occurrence of loss of heterozygosity (LOH) of tumor suppressor genes. In combination with inactivation of the other allele by genetic alterations, such as point mutations or gene silencing due to aberrant hypermethylation or possibly due to the naturally implemented genomic imprinting, it may lead to complete loss of expression of the affected tumor suppressor genes, such as p16 INK4A , p53 and Rb. (3) Global changes of gene expression may be caused by CIN, because either loss or gain of a whole or even a portion of a chromosome simultaneously affects thousands of genes. Such massive changes in the gene expression profile would provide a force sufficient to alter the physiological balance of various cellular systems, such as cell cycle checkpoints, metabolic and cell cycle machineries, and cell-to-cell communications. Since these may in turn lead to relaxation of the precise control of cell growth and genomic fidelity, it would consequently give cancer cells an excellent opportunity to efficiently change their phenotypes so as to be more malignant and suitable to their microenvironment.
Potential involvement of various malfunctions of cells in the induction of CIN
The consequence of CIN can be reflected as numerical and structural alterations of chromosomes, with the former often termed aneuploidy, while the latter includes deletion, translocation, HSR and DMs. These changes are not mutually exclusive, and in fact they are usually detected in the same cells, perhaps because of considerable overlap in the underlying mechanisms as we discuss below. The cells pass through an organized series of controlled events referred to as the cell cycle during proliferation. In addition to the machinery necessary for promoting cell cycle progression, cell cycle checkpoints are built-in as a monitoring system, which arrests cells at a particular phase of the cycle in response to a lack of appropriate signals for cell cycle progression, thereby maintaining the genetic stability and ensuring a smooth progression through the cell cycle (Hartwell and Weinert, 1989) . Thus, defects in either cell cycle machinery or checkpoints are likely candidates for the underlying mechanism of CIN ( Figure 1 ). In addition, other malfunctions of cells, such as telomere erosion, may be involved in the generation of CIN. In the following sections, these possible underlying mechanisms of CIN are discussed in reference to recent findings in lung and other human cancers as well as to those in various experimental systems.
Numerical CIN and its potential causes
Mitosis consists of spatially and temporally organized complex events including nuclear envelope breakdown, centrosome-mediated nucleation of new microtubules, condensation and movement of chromosomes, and cytokinesis. Failures in any of these events would induce CIN (Figure 2 ). The mitotic spindle checkpoint is activated by kinetochores that remain unattached to the spindle and delays the cell cycle at prometaphase until all chromosomes have established bipolar attachment. Although the precise signaling mechanism of the mitotic spindle checkpoint remains to be clarified, accumulating evidence points to an important role of the Bub and Mad genes (Amon, 1999; Rundner and Murray, 1996) . The presence of an unattached kinetochore is detected by a presently unknown mechanism, and a complex of the Bub and Mad gene products is then recruited to the unattached kinetochore, transmitting an activating signal to Mad2 and BubR1 (Shah and Cleveland, 2000; Wassmann and Benezra, 2001; Hoyt, 2001 ).
The Bub and Mad genes are conserved well in mammalian genomes as well as in lower eukaryotes such as yeast, in which they were originally identified in the analyses of mutants that failed to arrest in response to microtubule-depolymerizing drugs. The activated Mad2 inhibits anaphase promoting complex/cyclosome (APC/C), which is a multi-subunit E3 uniquitin ligase associated with proteosome-mediated proteolysis, through association with p55CDC. Since activation of APC/C, which promotes the degradation of Securin by 26S proteosome, is a prerequisite for the sisterchromatid separation, the inhibition of APC/C consequently arrests the cell at prometaphase.
Considering the importance of the mitotic spindle checkpoint in normal chromosome segregation, it is a good candidate for the mechanism, defects of which may be involved in the genesis of numerical CIN. Indeed, Cahill et al. (1998) have reported that the presence of the CIN phenotype in colon cancer cell lines was tightly associated with dysfunction of the mitotic spindle checkpoint. A significant fraction (up to 40%) of lung cancer cell lines also exhibit mitotic spindle checkpoint defects , but CIN in lung cancer appears to be less closely related to the presence of mitotic spindle checkpoint impairment than that in colon cancer , suggesting the possibility that cancer type-specific differences may exist in the major underlying causes of CIN between these two common cancers of adults.
Mutations in the mitotic spindle checkpoint genes have been reported in a small fraction of several types of human cancers including lung and colon cancers, including MAD1 in lung cancer , MAD2 in breast and bladder cancers (Percy et al., 2000; Hernando et al., 2001) , BUB1 in lung and colorectal cancers (Gemma et al., 2000; Sato et al., 2000; Cahill et al., 1998) , and BUBR1 in colon cancer (Cahill et al., 1998) . Considering the frequent occurrence of mitotic spindle checkpoint impairment in lung , colon (Cahill et al., 1998) , and nasopharyngeal cancers (Wang et al., 2000) as well as possibly in other types of human cancers, the relative scarcity of alterations in the mitotic spindle checkpoint genes may point to the possibilities of an inactivating mechanism other than mutation or an as yet unidentified major target gene responsible for the mitotic spindle checkpoint defects. It is also possible that there might be a large number of affected genes each playing a role in a small proportion of cases. In this connection, it is interesting to note that haploinsufficiency of the MAD2 gene resulted in a defective mitotic spindle checkpoint in both human cancer cells and murine primary embryonic fibroblasts (MEFs) and that mad2 (+/7) mice developed lung tumors at unusually high rates after long latencies (Michel et al., 2001) . Frequent loss of heterozygosity in 4q, where MAD2 resides, has been reported in lung cancer (Petersen et al., 1997a,b; Girard et al., 2000; Ullmann et al., 2001; Pei et al., 2001) as well as in other types of human cancers including Hodgkin's disease, hepatocellular carcinomas, and breast cancers (Dohner et al., 1992; Rashid et al., 1999; Shivapurkar et al., 1999) .
Several lines of evidence suggests the possibility that inactivation of a colon tumor suppressor protein, APC, may also lead to CIN. The C-terminal domain of APC binds to microtubules as well as to a protein called EB1. It has been shown that the EB1 protein associates at the spindle microtubules and centrosomes, and functions in the cytokinesis checkpoint (Muhua et al., 1998) . Recently, APC was also suggested to play a role in kinetochore-microtubule attachment, whereas truncated mutations of APC, which eliminate microtubule binding, induce chromosomal missegregation and the CIN phenotype (Kaplan et al., 2001; Fodde et al., 2001) . Tighe et al. (2001) recently reported that introduction of a mutant APC into a non-CIN colorectal cancer cell line with the intact mitotic spindle checkpoint impaired mitotic delay following Figure 2 Possible defects of the mitotic machinery involved in the generation of missegregation of chromosomes. Failure of anchoring of mitotic spindle to kinetochore, abnormal centrosome formation, abnormal chromosome separation and failure of cytokinesis can cause missegregation of chromosomes and CIN Chromosome instability in lung cancer A Masuda and T Takahashi spindle damage, providing additional support for its possible involvement. Although p53 was once suggested to play a role in the mitotic checkpoint, it is now well accepted that p53 is involved in the post-mitotic checkpoint, where it prevents endoreduplication (Lanni and Jacks, 1998; Khan and Wahl, 1998; Notterman et al., 1998) . Scolnick and Halazonetis (2000) recently identified a gene, named CHFR, which appears to coordinate another important phase of cell cycle progression, i.e., mitotic prophase. Interestingly, they also identified a loss of CHFR expression in one neuroblastoma and two colon cancer cell lines, although the molecular mechanism underlying the inactivation remained unclear. Mizuno et al. (2002) found that CHFR transcripts were undetectable in a fraction of lung cancer cell lines and that this appeared to be due to aberrant hypermethylation of the promoter region of CHFR, although it remains to be clarified whether loss of CHFR directly contributes to the acquisition of CIN.
Defects or abnormal regulation of molecules constituting the mitotic machinery may also induce missegregation of chromosomes, and thus they are candidates for the causes of CIN in human cancers. Centrosomes, which consist of a pair of centrioles surrounded by a pericentriolar protein matrix, play a pivotal role in organizing the microtubule network in interphase and the mitotic spindle at M phase. Inappropriate centrosome duplication and multipolar mitosis was first suggested by Boveri to be related to the chromosome abnormalities seen in cancer (Boveri, 1914) . Abnormal centrosomes are commonly seen in a wide range of cancers including lung, breast, prostate, brain, and colon cancers (Lingle et al., 1998; Pihan et al., 1998) . Centrosomes of tumor cells display diverse structural alterations including an increase in their number and size, accumulation of excess pericentriolar material, supernumerary centriole and inappropriate phosphorylation of centrosome proteins (Salisbury et al., 1999; Doxsey, 2001) . Normal cells duplicate a centrosome only once at the S phase during the cell cycle, while cyclin E and cyclin A have been suggested to play a role in centrosome duplication (Meraldi et al., 1999; Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et al., 1999) , possibly through nucleophosmin/B23 modification . Increased expression of pericentrin and g-tubulin, the components of centrosomes, are often detected in tumor cells, suggesting their potential contribution to CIN through formation of disorganized mitotic spindles (Pihan et al., 1998; Shu and Joshi, 1995) .
Recent experimental evidence suggests relationships between various genetic lesions and centrosome abnormalities in human cancers. While overexpression of cyclin E is common in human cancers (Keyomarsi and Herliczek, 1997) , overexpression of cyclin E and loss of p53 has been shown to synergistically induce centrosome hyperamplification and CIN in mouse embryonic fibroblasts (MEFs) (Mussman et al., 2000) , whereas Spruck et al. (1999) reported significant induction of CIN without accompanying centrosome abnormalities by conditional overexpression of cyclin E alone using tet/tTA gene-induction system. It was also reported that introduction of the Aurora-A centrosome-associated kinase, which is frequently overexpressed in multiple types of human cancers (Sen et al., 1997; Bischoff et al., 1998; Zhou et al., 1998) , induced abnormal centrosomes and transforms rodent fibroblastic cell lines (Bischoff et al., 1998; Zhou et al., 1998) . Overexpression of other centrosomeassociated kinases such as Aurora-B and Aurora-C has also been reported in human colon cancers (Katayama et al., 1999; Takahashi et al., 2000) .
The p53 tumor suppressor protein may also participate in the regulation of centrosome duplication. Multiple copies of functionally competent centrosomes are generated during a single cell cycle in MEFs lacking p53 (Fukasawa et al., 1996) , while introduction of p21, a target of p53-dependent transactivation, partially restores the centrosome duplication control in p53-deficient cells (Tarapore et al., 2001) . MEFs from mice lacking Gadd45a, another target of p53-dependent transactivation, shows centrosome amplification, unequal segregation of chromosomes due to multiple spindle poles, and the induction of aneuploidy (Hollander et al., 1999) . Ectopic overexpression of Mdm2, which inactivates p53, induces centrosome hyperamplification and CIN in Swiss 3T3 cells (Carroll et al., 1999) . Human papilloma virus-E6 (HPV-E6) oncoprotein, which inactivates p53, cooperates with the Rb-inactivating HPV-E7 oncoprotein, resulting in the induction of abnormal centrosomes, aberrant mitotic spindle pole formation and genomic instability (Duensing et al., 2000) . Thus, the most frequently and widely inactivated tumor suppressor protein, p53, seems to have a regulatory role in the process of centrosome duplication, and this may be one of the mechanisms by which inactivation of p53 function contributes to the induction of CIN.
Changes in other molecules of the mitotic machinery may also cause missegregation of chromosomes and consequently confer the CIN phenotype, when overexpressed, mutated or functionally abrogated (Pihan and Doxsey, 1999) . While ectopic expression of Securin, a sister-chromatid separation inhibitor, transforms NIH3T3 (Zou et al., 1999) , up-regulation of Securin has been reported in some human tumors (Saez et al., 1999; Heaney et al., 2000) . A human colorectal cancer cell line engineered to be securin deficient was shown to be abnormal in chromosome segregation, and to lose chromosomes at a high frequency (Jallepalli et al., 2001) .
Oncogenes may also be involved in the genesis of CIN. Introduction of ectopic vav-2 and mos oncogenes have been shown to induce cytokinesis abnormalities by uncoupling of nuclear division and cytokinesis, and to frequently induce multinucleation and abnormal spindles, resulting in CIN (Schuebel et al., 1998; Fukasawa and Vande Woude, 1997) . Several lines of evidence also point to a role of mutational activation of the ras genes, which are known to be present in certain types of human cancers including lung adenocarcinomas. Abnormal mitotic figures, mainly characterized by lagging chromosomes in prometaphase, and the resulting various ranges of aneuploidy were frequently observed in NIH-3T3 expressing activated human K-ras (Hagag et al., 1990; Nigro et al., 1996) . Increased karyotypic alterations were also observed in a chromosomally stable human colorectal cancer cell line, SW480, in proportion to the expression levels of ectopic human c-H-ras (de Vries et al., 1993) .
Structural instability and its potential causes
Complex structural aberrations of chromosomes are frequently seen in common epithelial tumors of adults including lung cancer, suggesting the presence of persistent structural CIN, although yet to be formally proven by future experimentation. DSBs can be introduced into the genome by intracellular stresses such as oxidative stress as well as by environmental stresses such as ionizing irradiation. DSBs are the most detrimental form of DNA damage, since they can cause erroneous rejoining of the broken genome, conferring a high risk for gross chromosomal structural abnormalities such as deletion, translocation, HSR and DMs. As a consequence, loss of a chromosomal segment may uncover an inactivating mutation occurring in the other allele of a tumor suppressor gene, whereas significant overrepresentation of a chromosomal region may lead to overexpression of protooncogenes and/or the induction of multidrug resistance against chemotherapy (Figure 3) .
The DNA damage checkpoints prevent damaged cells from starting DNA replication (the G 1 /S checkpoint), from progressing with replication (the intra S checkpoint) or from going into mitosis (the G 2 checkpoint) (Rotman and Shiloh, 1999; Dasika et al., 1999) . Mounting evidence indicates that the p53 gene is involved in the DNA damage checkpoints through various pathways, and the fact that p53 is one of the most frequent targets for somatic alterations in various types of human cancers including lung cancer indicates its important role as a guardian of the genome against various genomic insults. The ATM protein kinase signals the occurrence of DNA damage to p53 by phosphorylated serine 15 of p53 as well as threonine 68 of Chk2, an activated form of which in turn phosphorylated p53 at serine 20. These modifications stabilize, activate, and execute the effects of p53 by transcriptional activation of various target genes such as p21 and 14-3-3s (Harper et al., 1993; el-Deiry et al., 1993; Hermeking et al., 1997) . p21 inhibits various cyclin-dependent kinase activity including CDK2/cyclin E, resulting in the cell cycle arrest at the G 1 /S boundary. 14-3-3s excludes Cdc2/cyclin B from the nuclei, leading to cell cycle arrest at G 2 . p53R2, a novel inducible form of a catalytic subunit of ribonucleotide reductase, was recently identified as a downstream target of p53 and was implicated in DNA repair, providing intriguing evidence for a linkage between cell cycle checkpoints and DNA repair by p53 (Yamaguchi et al., 2001) . It was recently proposed that cells severely damaged to an unrepairable extent may be eliminated by the p53-dependent activation of p53DINP1 and its downstream molecule p53AIP1 (Oda et al., 2000; Okamura et al., 2001) . Among these downstream genes of p53, inactivation of 14-3-3s due to aberrant hypermethylation of its promoter region has been shown to be frequent in several common cancers of adults including lung, breast, gastric, and hepatocellular carcinomas (Ferguson et al., 2000a; Suzuki et al., 2000; Iwata et al., 2000; Osada et al., 2002) . Although ATM appears to play a key role in the upstream of p53 in the cellular response to DNA damage, somatic disruption of both alleles of the ATM gene is rarely observed. In this connection, it is of note that somatic ATM aberrations were recently reported in sporadic Bcell chronic lymphocytic leukemia (Schaffner et al., 1999) . In addition, individuals heterozygous for ATM mutations may possibly have an increased risk for cancer susceptibility (Khanna, 2000) . The S phase checkpoint is less well understood in terms of its possible contribution to the generation of chromosomal aberrations. A recent study shows that the S phase checkpoint is activated at least in part through the ATM-Chk2-Cdc25A pathway and that overexpression of Cdc25A cancels the S checkpoint signal through inhibition of CDK2 activity, which is needed for DNA synthesis (Falck et al., 2001) . Interestingly, overexpression of Cdc25A has been reported in 60% of NSCLC (Wu et al., 1998) .
The G 2 checkpoint prevents cells from entering into mitosis with broken chromosome. If the G 2 checkpoint fails to provide sufficient time for repair of DNA damage before entering mitosis, cells will have to deal with a chromosome broken into the centromeric and the acentric fragments. The fate of broken chromosomes in such a situation includes degradation, healing as a truncated chromosome, and generation of a Figure 3 Cellular responses to DNA double-strand breaks (DSBs). The occurrence of DSBs may be repaired by the activation of cell cycle checkpoints and DNA damage repair systems, whereas cells with extensive damage may be eliminated by the induction of cell death. Impairment of these systems can lead to genomic instabilities including chromosomal aberrations translocated chromosome due to fusion between two chromosomes. Fusion between two centromerecontaining chromosomes results in the formation of a chromosome with two centromeres, i.e., dicentric chromosome, which lacks a considerable portion of genetic material. Such a dicentric chromosome will be broken in the next mitosis, after which it fuses again, thus entering the highly unstable breakage -fusionbridge (BFB) cycle (McClintock, 1938 (McClintock, , 1940 Gisselsson et al., 2000) (Figure 4) . BFB cycles are also thought to play a role in the chromosome rearrangement and gene amplification.
Significant data has been accumulated during the past few years with regard to the molecules and signal transduction pathways involved in the G 2 checkpoint (Taylor and Stark, 2001; Dasika et al., 1999; Khanna, 2000) . Of particular relevance in terms of DNA damage response of this checkpoint is phosphorylation and subsequent activation of Chk1 and Chk2, which is thought to be mediated preferentially by ATR and ATM, respectively. Their activation leads to phosphorylation of Cdc25C, a phosphatase that normally activates Cdc2, and results in Cdc25C being bound to the 14-3-3 proteins and consequentially inactivated. It is of interest that Konishi et al. (2002) recently identified the presence of abnormal G 2 checkpoint response in a significant fraction of SCLC cell lines as well as a homozygous deletion of 14-3-3e in a SCLC cell line. Another member of the 14-3-3 family, 14-3-3s, which is transactivated by p53 in response to DNA damage, has been shown to have a role in the maintenance of G 2 arrest through nuclear exclusion of the Cdc2/cyclin B1. Somatic knockout cells of 14-3-3s show a loss of the normal G 2 checkpoint response to DNA damage and an accumulation of chromosomal aberrations (Chan et al., 1999; Dhar et al., 2000) . In this connection, frequent epigenetic inactivation of 14-3-3s due to aberrant hypermethylation has been reported in lung cancer as well as in a few other types of human cancers including breast, gastric and hepatocellular carcinomas Ferguson et al., 2000a) . Additional evidence for the involvement of molecules implicated in the G 2 checkpoint is provided by the demonstration of germline CHK2 mutations in family members of the Li-Fraumeni syndrome, who do not carry p53 mutations in their germline. CHK2 has also been shown to be somatically mutated in a small fraction of lung cancer (Haruki et al., 2000; Matsuoka et al., 2001) .
Two distinct and complementary mechanisms, which are termed non-homologous end joining (NHEJ) and homologous recombination (HR), are installed in cells for repair of detrimental DSBs, which can cause chromosomal structural abnormalities resulting from its erroneous rejoining of the broken genome. These two repair pathways differ in their requirement for a homologous template DNA and in the fidelity of DSB repair. In contrast to generally error-free HR, NHEJ is an error-prone pathway that joins DNA ends with no sequence homology or those with a short homologous sequence (510 bp), termed microhomology (Khanna and Jackson, 2001; Ferguson and Alt, 2001) (Figure 5 ).
Rad50-Mre11-NBS1 complex plays an important role in both HR and NHEJ pathways by processing Figure 4 The breakage -fusion -bridge (BFB) cycle resulting from DNA double-strand breaks. (a), A broken chromosome is replicated, resulting in two chromatids. After fusion of these chromatids at their ends by NHEJ, the chromosome breaks again at a secondary site, and enters the BFB cycle. (b), Two broken chromosomes are fused with one another to form a dicentric chromosome with two centromeres. At mitosis, the chromosome breaks again at a secondary site, if the two centromeres are pulled to opposite sides by mitotic spindles, and enters the BFB cycle. (c), A chromosome broken at plural sites is fused with itself to form a ring chromosome. Torsion or chromatid exchange during replication leads to the formation of a chromosome with two centromeres. At mitosis, the chromosome breaks again at two secondary sites, when the two centromeres are pulled to opposite sides by mitotic spindles, and enters the BFB cycle DSBs prior to its repair. While NBS1 is phosphorylated by ATM in response to DNA damage, germline NBS1 mutations leads to Nijmegen breakage syndrome (NBS), an A-T like hereditary cancer prone disorder with CIN, developmental defects, and radiosensitivity (Petrini, 2000; Carney, 1999) . MRE11 mutations have been found in patients of another A-T-like disorder AT-LD as well as in a small fraction of breast and lymphoid tumors (Stewart et al., 1999; Fukuda et al., 2001) . ATM-dependent, c-Abl-mediated phosphorylation of Rad51 increases the association between Rad51 and Rad52, which play a role in HR repair. It is notable that other proteins implicated in the orchestration of a proper Rad51 response include the breast tumor suppressor Brca1 and Brca2. It seems that Brca1 interacts indirectly with Rad51, whereas Brca2 binds directly to Rad51 (Chen et al., 1998; Davies et al., 2001) . Both Brca1 and Brca2 co-localize with the Rad proteins in radiation-induced foci (Scully and Livingston, 2000) . Embryonic lethality in Brca1-or Brca2-deficient mice is attenuated by deficiency of p53 (Hakem et al., 1997; Sharan et al., 1997) . Loss of either Brca1 or Brca2 leads to aneuploidy in association with centrosome amplification and chromosomal missegregation (Xu et al., 1999b; Lee et al., 1999) . While tumors in Brca2-deficient mice have been shown to carry mutations in the mitotic spindle checkpoint genes Bub1 or Mad3L , loss of p53 accelerates the formation of mammary tumors in mice carrying conditional mutation of Brca1 (Xu et al., 1999a) . A DNA-dependent helicase Rad54, which plays a role in a later step of HR in association with Rad51, as well as its homologue RAD54B have been shown to be mutated in human lymphoma, colon cancer and breast cancer (Hiramoto et al., 1999; Matsuda et al., 1999) .
In the process of NHEJ repair, the DNA-dependent protein kinase (DNA-PK), which is a member of PI3-kinase related kinases consisting of a heterodimeric DNA targeting subunit (Ku70 and Ku80) and a catalytic subunit (DNA-PKcs), plays a role as one of the key components. DNA Ligase4 (Lig4) and XRCC4 catalyze the DNA ligation step in the process of NHEJ. Defects in any of Ku70, Ku80, XRCC4 or Lig4 have been shown to generate frequent chromosome and chromatid breaks, premature cellular senescence and apoptosis in their respective knockout mice (Bailey et al., 1999; Difilippantonio et al., 2000; Ferguson et al., 2000b; Gao et al., 2000; Karanjawala et al., 1999) . Embryonic lethality and premature senescence of fibroblasts in NHEJ-deficient mice can be rescued by simultaneous deficiency of p53, and they develop progenitor B cell lymphomas (Difilippantonio et al., 2000; Guidos et al., 1996; Vanasse et al., 1999; Frank et al., 2000) . LIG4 mutation was recently reported in a leukemic patient, who was highly radiosensitive (Riballo et al., 1999) .
Gene amplification of certain oncogenes, including members of the ERBB and MYC gene families, is occasionally present in various human cancers including lung cancer (Brison, 1993) , where it is often reflected as HSR and DMs in karyotyping analysis. The frequencies of gene amplification increase in association with increase in tumor stage, suggesting that the event may be involved in tumor progression rather than in initiation. Although the molecular mechanisms of gene amplification are not fully understood, it has been suggested that DSBs near the amplified gene, incorrect repair and the resulting BFB cycle may be involved in the genesis of gene amplification (Singer et al., 2000) . Quantitative measurements have indicated that gene amplification of the CAD gene can be induced in response to N-(phosphonoacetyl)-L-aspartate (PALA) treatment at a higher rate (10 73 -10 75 ) in cancer cells than that (510 79 ) in normal cells (Tlsty et al., 1989; Tlsty, 1990) . Notably, p53-deficient human fibroblasts have been shown to be more vulnerable to CAD gene amplification than the proficient cells (Livingstone et al., 1992; Yin et al., 1992) , suggesting that p53 inactivation may play a role in this type of genetic instability.
Another important clue for a better understanding of the underlying mechanisms of CIN came from recent progress in the studies on telomere and telomerase, i.e., possible involvement of progressive telomere erosion in the acquisition of CIN in cancer cells (Harley and Sherwood, 1997; . Even though telomeres are essential for normal chromosome structure and function, they cannot be fully replicated by the conventional DNA polymerase complex. Normal somatic cells show a progressive loss of their telomere DNA during proliferation, whereupon they enter replicative senescence, a non-proliferating, but metabolically active stable state, which often accom- Figure 5 The double-strand break (DSB) repair by either nonhomologous end-joining (NHEJ) and homologous recombination (HR). NHEJ pathway (left). The Ku heterodimer binds to DNA ends and recruits DNA-PKcs, while Mer11/Rad50/NBS1 are thought to have enzymatic and/or structural roles. The XRCC4/ Ligase IV complex joins the DNA ends. HR pathway (right). DSBs are initially processed by the Mre11/Rad50/NBS1 nuclease complex. Rad52 protects DNA ends and RAD51 facilities DNA strand invasion. Intact DNA from the sister chromatid or homologous chromosome is used as a template panies generation of polyploid cells (Sherwood et al., 1988) . In contrast, it is presumed that premalignant/ cancer cells, which have lost normal control of proliferation due to the activation of oncogenes and inactivation of tumor suppressor genes, continue to proliferate, resulting in the extensive telomere shortening. This may consequently lead to telomere association and subsequent formation of structurally abnormal chromosomes, such as dicentric and ring chromosomes. The resultant structurally abnormal chromosomes are notably unstable by nature and undergo the BFB cycle, providing the driving force behind continuous generation of structurally abnormal chromosomes (Counter et al., 1992) .
Several lines of evidence suggest the occurrence of telomere dysfunction in carcinogenesis. Human fibroblasts senesce and cease proliferation, which is accompanied by activation of p53 as well as increased expression of p21, p16
INK4A and p14 ARF (Atadja et al., 1995; Kulju and Lehman, 1995; Alcorta et al., 1996; Dimri et al., 2000) . p53-and Rb-inactivating oncoproteins of viral origin such as SV40 large T, HPV-E6/E7 and adenovirus E1A/E1B drive presenescent cells into extended proliferation and result in the crisis (Shay et al., 1991; Counter et al., 1992) (Figure 6 ). Lack of the p21 gene allows continued cell division despite increasing telomere dysfunction, leading to telomere crisis in p21-deficient, otherwise normal human fibroblasts (Brown et al., 1997) . Notably, telomerasedeficient mice of successive generational matings not only exhibit a subset of premature aging phenotypes but also develop spontaneous tumors at a high rate, suggesting a role of telomere erosion due to its extensive shortening (Rudolph et al., 1999; . It is notable that serial retroviral transduction of primary human fibroblast with SV40 large T, activated H-ras, and then hTERT resulted in transformation and tumors in nude mice (Hahn et al., 1999) , in contrast to the failure of anchorage-independent growth of fibroblasts, which were serially transduced with hTERT, E6/E7 and then activated H-ras . These findings suggest that the ordered occurrence of telomere crisis and subsequent reexpression of telomerase may be a requisite for malignant transformation. The precise molecular mechanism involved in the re-expression of telomerase in cancer cells remains to be elucidated, but several possible candidates have recently been proposed. Members of the Myc gene family directly transactivate hTERT (Wang et al., 1998; Wu et al., 1999) , while Mad, an antagonizing binding partner of Myc, represses hTERT gene expression (Oh et al., 2000) . High hTERT mRNA levels have been suggested to be linked to myc gene overexpression in various human cancers (Latil et al., 2000; Bieche et al., 2000; Sagawa et al., 2001) . Introduction of HPV-E6 also stimulates the expression of hTERT through activation of unidentified transcription factors that share the binding site with Myc and Sp1 (Klingelhutz et al., 1996; Oh et al., 2001) . Interestingly, microcell transfer experiments have revealed that a gene or genes that represses expression of hTERT may be present on human chromosome 3p, which is among the most frequently altered regions in lung cancer (Ohmura et al., 1995; Cuthbert et al., 1999) .
Current understanding and perspective on future studies of the molecular basis of CIN in lung cancer
There are many theoretically possible candidates for the underlying mechanisms that would cause CIN in lung cancer, if one takes experimental data in yeast into consideration of human cancers. In this section, we will discuss the current status and perspective on the studies of potential underlying mechanisms of CIN in lung cancer as well as the direction of future studies, based on the molecular genetic and cytogenetic findings thus far identified in this tumor type.
Many molecules or pathways can be nominated as a potential candidate for lesions, alterations of which may directly contribute to the acquisition of the CIN phenotype in human lung cancer. One such example would be an abnormal centrosome. It is well recognized that centrosomes are frequently overrepresented in lung cancer with significant atypia in shape, size, and composition (Pihan et al., 1998) . A fairly good correlation has been reported between centrosome abnormalities and the CIN phenotype in lung cancer cell lines ). As discussed above, orderly duplication of centrosomes requires regulated expression of cyclin E and cyclin A, and overexpression of cyclin E has been shown to induce centrosome abnormalities and numerical CIN in combination with loss of p53 in rodent embryonic fibroblasts (Spruck et al., 1999; Mussman et al., 2000) . In this context, frequent overexpression of cyclin E and cyclin A has been shown in lung cancer (Volm et al., Figure 6 Excessive shortening (erosion) of telomere and the occurrence of cancer cells with CIN. Telomere shortening in primary human cells leads to p53 and Rb-dependent replicative senescence, whereas cells with inactivated p53 and Rb continue to divide, entering telomere crisis due to telomere erosion. Reactivation of telomerase, which is observed in 80 -90% of lung cancers, allows cells to escape from telomere crisis. Note that telomere erosion may lead to the formation of unstable chromosomes such as dicentric and ring chromosomes, which are susceptible to entering the BFB cycle (See text and Figure 4) 1997; Dobashi et al., 1998; Mishina et al., 2000; Fukuse et al., 2000) . In addition, frequent genetic and epigenetic alterations present in lung cancer may be associated with the induction of CIN in this scheme. Mutations in the RB gene, which are frequent especially in SCLC (Harbour et al., 1988) , may conceivably result in the deregulated expression of cyclin E and cyclin A through the consequential E2F-mediated transactivation (Harbour and Dean, 2000) , which would in turn confer CIN to lung cancer cells. Inactivation of p16
INK4A due to aberrant hypermethylation, which is present almost exclusively in NSCLC, may have similar consequences in terms of the generation of CIN, because loss of p16 INK4A impairs its negative regulatory function on the CDK4 activity that inhibits Rb function.
Another important candidate is defects in the mitotic spindle checkpoint. Lung cancer cells lines have been shown to carry mitotic checkpoint defects up to 40% and those with such defects indeed exhibited persistent ongoing CIN . It is notable that despite relatively frequent mitotic spindle checkpoint impairment, mutations and down-regulations of the mitotic spindle checkpoint genes are infrequent in human lung cancer Gemma et al., 2000; Sato et al., 2000) . Collectively, these findings suggest that although the impaired mitotic spindle checkpoint may have a certain role as a CIN-inducing lesion in lung cancer, we seem to have a missing piece(s) allowing a better understanding of how it is introduced. In this connection, Tighe et al. (2001) recently showed that abrogation of a colon tumor suppressor APC's function in a non-CIN colon cancer cell line induced chromosomal missegregation and the CIN phenotype despite retention of a robust mitotic spindle checkpoint. They also reported the presence of APC mutations correlated well with the CIN phenotype in colon cancer cell lines. Although APC mutations have not been reported in lung cancer, it would be an intriguing possibility that alterations of the signaling pathway involving APC might play a part in the genesis of CIN in lung cancer.
The recent finding of frequent G 2 checkpoint impairment in SCLC is of considerable interest in terms of CIN as well as other aspects . Cells with such a defect may well be susceptible to loss of chromosomes in mitosis or initiation of the BFB cycles as discussed above, while up to 90% of SCLCs carry p53 mutations. It has been shown that G 2 checkpoint-overriding agents such as caffeine and pentoxyphylline enhance the sensitivity of cells that are defective in the G 1 /S delay to DNA damaging agents (Fan et al., 1995; Powell et al., 1995; Russell et al., 1995) . These findings may therefore be consistent with the notion that SCLC is sensitive to chemo-and radiotherapy but often recurs after the initial successful treatment, showing aggressive clinical behavior. Although a few genes related to the G 2 checkpoint have been found to be inactivated in lung cancer (Haruki et al., 2000; Konishi et al., 2002; Osada et al., 2002) , further studies are necessary to identify an additional molecule(s) that may account for the high frequency of G 2 checkpoint aberrations in SCLC as well as to examine the contribution of the perturbed G 2 checkpoint in the progression of lung cancer.
Structural abnormalities in chromosomes are commonly seen in lung cancer, suggesting the existence of defects in the DSB repair systems. Although the potential involvement of defects in the DSB repair system is conceivable, no direct evidence has yet been obtained, and this is obviously an area requiring thorough future investigation. In addition, human orthologues of various genes that, when altered, can result in CIN phenotypes in lower eukaryotes, such as yeast, would be excellent candidates for such as yet unidentified genetic lesions (Chen and Kolodner, 1999) .
Accumulating evidence suggests that telomere erosion and consequential formation of abnormal chromosomes, such as dicentric and ring chromosomes may also be involved in the acquisition of CIN as discussed above. In this connection, telomere lengths of lung cancer are often significantly shorter than the normal case, and telomerase is re-activated in more than 80% of lung cancers (Hiyama et al., 1995a,b) . It should prove interesting to investigate the timing of these changes in premalignant lesions, since the order of occurrence of telomere crisis and re-expression of telomerase has been suggested to be crucial in terms of neoplastic transformation .
p53 mutations are among the most frequent genetic lesions thus far identified in lung cancer (Takahashi et al., 1989) , and it has been shown that both inactivation of p53 and aneuploidy are detectable even in the dysplastic lesions of the lung (Sundaresan et al., 1992; Nuorva et al., 1993; Hirano et al., 1994) . In addition, up-regulation of MDM2 and down-regulation of p14 ARF , both of which inactivate p53 function, are also detectable in a fraction of NSCLC (Higashiyama et al., 1997; Vonlanthen et al., 1998) . Accumulating evidence, however, suggests that inactivation of p53 may be indirectly involved in the induction of CIN in lung cancer by permitting cells to proliferate in the presence of defects, which directly lead to CIN. Haruki et al (2001) recently reported that inactivation of p53 allowed lung cancer cells to go through an inappropriate second division cycle under mitotic stresses, resulting in the induction of the CIN phenotype in conjunction with the generation of aneuploidy. Furthermore a similar permissive role of abrogation of p53 function has been shown to exist in diverse settings, which might have relevance to the generation of CIN in lung cancer. For example, p53 inactivation rescues knockout mice that have defects in DSB repair machineries from their lethality (Difilippantonio et al., 2000; Guidos et al., 1996; Vanasse et al., 1999; Frank et al., 2000) , while telomerase deficient MEFs are more readily transformable by cellular oncogene in cooperation with p53 deficiency (Chin et al., 1999) . It is interesting that growth defects in MEF from Brca2
Tr/Tr mice can be overcome and their cellular transformation promoted by the expression of dominant negative mutants of p53 or Bub1 (Lee et al., 1999) . These findings also reflect well the presence of p53 mutations as well as either Bub1 or Mad3L mutations in tumors arising in the Brca2
Tr/Tr mice, suggesting a strong selective pressure to remove DNA damage and mitotic spindle checkpoints during the transformation processes, which in turn consequently leads to the induction of CIN. Overexpression of anti-apoptotic genes such as BCL-2 and Survivin in lung cancer might provide the opportunity to resist apoptotic signals in a p53-independent manner (Pezzella et al., 1993; Monzo et al., 1999) . Finally, but no less importantly, once alterations of chromosomes are imposed in lung cells by the above mentioned mechanisms, the resultant chromosomal defects themselves may provide the driving force for maintaining persistent CIN because of the BFB cycle and potentially abnormal number of chromosomes itself (Gisselsson et al., 2000; Duesberg et al., 1998; Matzke et al., 1999) .
Growing evidence suggests the possible biological and clinical impact of CIN in the pathogenesis of lung cancer. However, currently available information is far from sufficient to envisage the precise roles of CIN. We have yet to identify which are the major underlying mechanisms of CIN as well as when CIN is introduced during the process of initiation and progression of this fatal disease. Also, it is important to elucidate how the presence of CIN in lung cancer cells contributes to the carcinogenesis and progression. To answer these important questions, systematic studies with regard to the molecular lesions involved will certainly be important. In addition, molecular correlative studies on the relationship of clinical characteristics of lung cancer patients with the presence of CIN and/or the lesions involved should give us important clues to a better understanding. Recent advances in the cutting edge technology for molecular cytogenetic and cellular biological studies as well as the enormous amount of information about the human genome should make it possible to further elucidate the molecular basis and clinical importance of CIN, eventually leading us to the development of new therapeutic approaches for this highly prevalent and aggressive form of cancer.
